Fluxion Biosciences joins BloodPAC consortium to accelerate liquid biopsy development
Participation will help advance liquid biopsy adoption by collaborating among key industry stakeholders
11 Jun 2020Fluxion Biosciences has announced that it has joined the BloodPAC (Blood Profiling Atlas in Cancer) industry consortium. BloodPAC includes major stakeholders in the development and clinical adoption of liquid biopsies, including test developers, cancer centers, pharmaceutical companies, and regulators such as the FDA.
Liquid biopsies offer the potential to improve treatment of cancer by providing affordable, non-invasive detection of actionable cancer mutations from a blood sample. However, numerous challenges remain in liquid biopsy development, including development of analytical samples, reference methods for calculation of test performance, and characterization of pre-analytical variables such as blood draw method, sample storage, and DNA extraction approaches. BloodPAC includes cross-industry teams working collaboratively to address these issues and accelerate the clinical adoption of this important new diagnostic.
Fluxion is joining BloodPAC after a working group successfully tested Fluxion’s ERASE-Seq liquid biopsy method. Analytical and clinical results have demonstrated that ERASE-Seq provides superior performance for NGS detection of somatic mutations from circulating tumor DNA (ctDNA). ERASE-Seq is currently available on a research use only (RUO) basis using Fluxion’s Spotlight oncology kits as well as custom panels.
“We are honored to join the industry-leading BloodPAC group, and are excited to advance the commercialization of liquid biopsies”, stated Jeff Jensen, Fluxion CEO. “Liquid biopsies offer tremendous promise, but advances are needed to improve the sensitivity and accuracy of these tests. We look forward to participating with other BloodPAC members in industry, academia, and government in this important program.”